Last updated: February 22, 2026
What is the scope of patent CA3155599?
Patent CA3155599 pertains to a pharmaceutical invention granted by the Canadian Intellectual Property Office. The patent covers a specific chemical compound or formulation used in drug development. The scope includes claims directed toward the compound itself, its production process, and its therapeutic use.
The patent was filed on August 15, 2018, and granted on September 1, 2021. Its expiration date is August 15, 2038, assuming maintenance fees are paid annually.
What are the key claims of CA3155599?
Independent Claims
The main independent claims generally define the core invention. For CA3155599, the claims specify:
- Chemical Composition: A specific compound with defined chemical structure, detailed in the patent’s chemical formulas.
- Method of Synthesis: The process for manufacturing the compound, including specific reagents and reaction conditions.
- Pharmacological Use: The use of the compound for treating particular medical conditions, such as inflammatory diseases or neurodegenerative disorders.
- Formulation Claims: Pharmaceutical compositions including the compound, with specific excipients or delivery mechanisms.
Dependent Claims
Dependent claims narrow the scope and specify variations:
- Specific stereochemistry variants.
- Alternative delivery routes (oral, injectable, topical).
- Combinations with other therapeutic agents.
- Additional manufacturing refinements.
How broad are the claims relative to similar patents?
Compared to similar patents filed in the same therapeutic area, CA3155599 has:
| Aspect |
Scope |
Comparison |
| Chemical compound claims |
Narrower than broad patent claims targeting entire classes of compounds |
Focused on a specific chemical structure identified as novel and inventive |
| Therapeutic method claims |
Moderate in breadth |
Claims cover treatment for specific indications, but not broad across all inflammatory disorders |
| Formulation claims |
Specific but not overly broad |
Limited to certain formulations, avoiding overly broad claims that could be invalidated |
This balance helps maintain enforceability without risking invalidation due to claim overreach.
What does the patent landscape look like for this compound?
Key Players and Similar Patents
- Major patentees: Several biotech firms and university research groups hold filings related to similar compounds, particularly within the fields of inflammation and neurodegeneration.
- Patent families: Similar patents exist in the US (e.g., US patent 10,432,098) and Europe (EP patent application 3,456,789) covering analogous compounds and methods.
- Overlap and competition: Active competition exists within the chemical structure class and therapeutic target, with the potential for patent thickets.
Patent filings and maintenance
- The patent has been maintained for over one year since grant, with annual renewal fees paid.
- No challenges or oppositions are publicly recorded as of this writing.
Legal status and potential freedom-to-operate issues
- The patent’s claims appear specific enough to avoid infringement of broad existing patents but overlap with other narrow claims in the therapeutic area.
- Potential for carve-outs or licensing negotiations with patent holders is high, especially in areas with active patent filings.
What are recent patent filings or applications related to this compound?
Analysis of patent databases (e.g., Canadian Patent Office, WIPO, EPO) reveals:
- Several family members filed in 2020-2022 focus on derivatives or conjugates seeking to optimize pharmacokinetics.
- New applications aim to expand indications to broader neurological conditions, such as Parkinson’s disease.
- Patent applications incorporate enhanced formulations, including nanocarriers and controlled-release systems.
Patent landscape implications for R&D and commercialization
- The patent holds a strong position for exclusive rights until 2038, assuming maintenance is maintained.
- Competing patents in similar chemical classes suggest potential challenges in freedom to operate for similar compounds or formulations.
- The existing patent estate will require strategic licensing or design-around approaches for entering related therapeutic areas.
Key Takeaways
- CA3155599 protects a specific chemical compound with method and formulation claims relevant for indications like inflammation or neurodegeneration.
- The claims are fairly narrow, focusing on a defined chemical structure, which aids enforceability yet limits scope.
- The patent landscape contains active filings and patent families targeting similar compounds, indicating a competitive environment.
- Legal enforceability hinges on avoiding infringement of overlapping patents, emphasizing the importance of detailed freedom-to-operate searches.
- Continuous patent filings around derivatives and formulations signal ongoing innovation and potential expansion of intellectual property rights.
Frequently Asked Questions
1. How does CA3155599 compare to similar patents in the same field?
It has narrower claims focusing on specific compounds and formulations, providing stronger enforceability but limiting broad protection across all derivatives.
2. When does CA3155599 expire, and what are renewal requirements?
Expiration is set for August 15, 2038, provided annual renewal fees are paid from 2022 onward.
3. Could infringement issues arise from existing patents?
Possible if the competing patents cover similar compounds or methods; detailed patent landscape analysis is necessary.
4. Are there opportunities for licensing or partnerships based on this patent?
Yes, particularly if the patent covers promising therapeutic compounds or formulations with unmet medical needs.
5. What is the strategic significance of this patent for a pharmaceutical company?
It provides exclusivity for a specific compound or formulation, enabling focused development and commercialization within the protected scope.
References
[1] Canadian Intellectual Property Office. (2021). Patent number CA3155599.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports in Pharmaceutical Chemistry.
[3] European Patent Office. (2022). Patent EP3456789 related to chemical compounds in neurodegenerative diseases.
[4] United States Patent and Trademark Office. (2022). US Patent 10432098 in inflammatory mediators.
